Adult Dosing

Prevention of acute nausea/vomiting in cancer chemotherapy

• 0.5 mg PO 1 hr before start of chemotherapy

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

• Prevention of acute nausea and vomiting associated with initial and repeat course of moderately emetogenic cancer chemotherapy

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: No dose adjustments

• Patients hypersensitive to other 5-HT3 receptor antagonists may exhibit hypersensitivity to palonosetron

Cautions: Use cautiously in

• Hx of constipation

Pregnancy Category:B

Breastfeeding: Safety unknown. Possible serious adverse reactions in nursing infants and potential for tumorigenicity shown in rat carcinogenicity study, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

• CV: QT prolongation
• CNS: Headache
• GI: Constipation
• MISC: Hypersensitivity, fatigue

• 5-HT3 antagonists; blocks the action of serotonin at 5-HT3 receptors
• Metabolized by liver; CYP450: 3A4, 1A2, and 2D6 (primary) substrates
• Renally excreted: Urine 85-93% (40% unchanged); feces: 5-8%
• Half-life: 48 +/- 19 hrs (cancer patients)

US Trade Name(s)

• Aloxi

US Availability

Aloxi

• CAPS: 0.5 mg

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

Gastrointestinal

Antiemetics

5HT3 Receptor Antagonists

Drug Name: Aloxi 0.5 MG Oral Capsule

Ingredient(s): Palonosetron

Imprint: N/A

Color(s): White

Shape: Oval

Size (mm): 3.00

Score: 1

Inactive Ingredient(s): mono- and di-glycerides of capryl/capric acid / glycerin / polyglyceryl oleate / water / butylated hydroxyanisole

Drug Label Author:
EISAI

DEA Schedule:
Non-Scheduled